226908-63-0

Upstream product

• 96-49-1 [1,3]-dioxolan-2-one 
• 7388-28-5 sodium 2-hydroxyethoxide 
• 56046-25-4 6-amino-9-benzyl-2-chloropurine 
• 7674-33-1 6-Amino-9-benzyl-9H-purin-2(3H)-one 
• 7674-36-4 9-Benzylpurine-2,6-diamine 

Downstream Products

• 226908-64-1 6-Amino-9-benzyl-8-bromo-2-(2-hydroxyethoxy)purine 
• 226908-65-2 6-Amino-9-benzyl-2-(2-hydroxyethoxy)-8-methoxypurine 

Relevant academic research and scientific papers

Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities

In order to create novel compounds which possess potent interferon (IFN) inducing activities with excellent oral bioavailabilities, a series of 8-hydroxyadenines, which have various alkoxy or alkylthio moieties at the adenine C(2)-position, were synthesiz

Heterocyclic compounds

The present invention relates to a heterocyclic compound of the following general formula (I): wherein X is sulfur atom, oxygen atom or —NR3— (R3may form a heterocyclic ring or a substituted heterocyclic ring with R1via the nitrogen atom), R1is alkyl group, substituted alkyl group, aryl group, substituted aryl group, heterocyclic group or substituted heterocyclic group, and R2is hydrogen atom, halogen atom etc.; or its pharmaceutically acceptable salt and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases comprising the compound (I) or its pharmaceutically acceptable salt as active ingredients.

Synthesis of acyclic nucleotide analogues derived from N3-substituted isoguanine

Reaction of 9-benzyl-6-{[(dimethylamino)methylidene]amino}purin-2(3H)-one (7) with ethylene carbonate gave a mixture of 9-benzyl-2-(2-hydroxyethoxy)purin-6-amine (10) and 2-amino-9-benzyl-3-(2-hydroxyethyl)purin-2(3H)-one (11). This mixture reacted with diisopropyl (tosyloxymethyl)phosphonate in the presence of NaH followed by catalytic hydrogenation and bromotrimethylsilane treatment to afford isomeric 6-amino-3-[2-(phosphonomethoxy)ethyl]purin-2(3H)-one (3) and 2-[2-(phosphonomethoxy)ethoxy]purin-6-amine (15). Similar treatment of compound 7 with tritylglycidol gave two isomeric 2-hydroxy-3-(trityloxy)propyl derivatives 18, 20 which were subsequently condensed with diisopropyl (tosyloxymethyl)phosphonate to afford protected diester intermediates 21 and 22; these compounds were transformed by hydrogenolysis and ester cleavage with bromotrimethylsilane to the isomeric 6-amino-3-[3-hydroxy-2-(phosphonomethoxy)propyl]-purin-2(3H)-one (2) and 2-[3-hydroxy-2-(phosphonomethoxy)propoxy]purin-6-amine (24). None of the free phosphonates 2, 3, 15 or 24 exhibited any antiviral or cytostatic activity.